Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1952 1
1953 1
1954 1
1955 1
1957 2
1958 1
1960 3
1961 9
1962 6
1963 16
1964 15
1965 10
1966 22
1967 13
1968 16
1969 17
1970 35
1971 24
1972 33
1973 23
1974 51
1975 31
1976 24
1977 32
1978 56
1979 39
1980 64
1981 85
1982 65
1983 100
1984 97
1985 101
1986 128
1987 101
1988 135
1989 153
1990 133
1991 144
1992 162
1993 151
1994 188
1995 182
1996 166
1997 183
1998 212
1999 243
2000 245
2001 244
2002 224
2003 221
2004 236
2005 272
2006 260
2007 257
2008 249
2009 289
2010 299
2011 346
2012 354
2013 326
2014 312
2015 330
2016 334
2017 345
2018 348
2019 351
2020 443
2021 500
2022 44
Text availability
Article attribute
Article type
Publication date

Search Results

9,347 results
Results by year
Filters applied: . Clear all
Page 1
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S. Wang R, et al. Among authors: matsumoto k. Nat Commun. 2020 Sep 14;11(1):4607. doi: 10.1038/s41467-020-18442-4. Nat Commun. 2020. PMID: 32929081 Free PMC article.
Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
Hasegawa S, Ikesue H, Nakao S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Inoue M, Satake R, Yoshida Y, Goto F, Hashida T, Nakamura M. Hasegawa S, et al. Among authors: matsumoto k. Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1279-1294. doi: 10.1002/pds.5108. Epub 2020 Sep 1. Pharmacoepidemiol Drug Saf. 2020. PMID: 32869941 Free PMC article.
Diseases related to Notch glycosylation.
Matsumoto K, Luther KB, Haltiwanger RS. Matsumoto K, et al. Mol Aspects Med. 2021 Jun;79:100938. doi: 10.1016/j.mam.2020.100938. Epub 2020 Dec 16. Mol Aspects Med. 2021. PMID: 33341260 Review.
Reply.
Matsumoto K, Jin Z, Homma S, Elkind MSV, Schwartz JE, Rundek T, Mannina C, Ito K, Sacco RL, Di Tullio MR. Matsumoto K, et al. J Hypertens. 2021 Jun 1;39(6):1261-1262. doi: 10.1097/HJH.0000000000002825. J Hypertens. 2021. PMID: 33967220 No abstract available.
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K. Hayashi H, et al. Among authors: matsumoto k. JAMA Oncol. 2020 Dec 1;6(12):1931-1938. doi: 10.1001/jamaoncol.2020.4643. JAMA Oncol. 2020. PMID: 33057591 Free PMC article.
Cyclic Peptide-Based Biologics Regulating HGF-MET.
Sato H, Imamura R, Suga H, Matsumoto K, Sakai K. Sato H, et al. Among authors: matsumoto k. Int J Mol Sci. 2020 Oct 27;21(21):7977. doi: 10.3390/ijms21217977. Int J Mol Sci. 2020. PMID: 33121208 Free PMC article. Review.
The history of femoroacetabular impingement.
Matsumoto K, Ganz R, Khanduja V. Matsumoto K, et al. Bone Joint Res. 2020 Sep 20;9(9):572-577. doi: 10.1302/2046-3758.99.BJR-2020-0003. eCollection 2020 Sep. Bone Joint Res. 2020. PMID: 33005396 Free PMC article.
9,347 results